Postherpetic Neuralgia (PHN) Market Report 2026

Postherpetic Neuralgia (PHN) Market Overview

• Postherpetic Neuralgia (PHN) market size has reached to $0.77 billion in 2025 • Expected to grow to $1.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Prevalence Of Chronic Pain Conditions Propelling The Growth Of The Market Due To Increasing Demand For Chronic Pain Management And Expanding Ageing Population • Market Trend: Regulatory Approvals Driving Growth In The Market Due To Expanded Access To Effective Treatments • North America was the largest region in 2025.

What Is Covered Under Postherpetic Neuralgia (PHN) Market?

Postherpetic neuralgia (PHN) is a chronic nerve pain condition that occurs as a complication following an outbreak of herpes zoster (shingles). It is characterized by persistent, often severe pain in the area where the shingles rash appeared, lasting for months or even years after the rash has healed. Postherpetic neuralgia (PHN) results from nerve damage caused by the varicella-zoster virus reactivation and is the most common complication of shingles, especially in older adults. The main types of postherpetic neuralgia (PHN) are patches, drugs, and opioids. Patches refer to transdermal drug delivery systems that are applied directly to the skin to provide a controlled release of medication into the bloodstream. It distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to end users, such as hospitals, clinics, ambulatory surgical centers, and others.

What Is The Postherpetic Neuralgia (PHN) Market Growth Forecast?

The postherpetic neuralgia (phn) market size is expected to see strong growth in the next few years. It will grow to $1.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of targeted neuropathic pain therapies, rising adoption of biologic and branded drugs, growth of online pharmacy distribution channels, increasing focus on patient-centric pain management, expansion of outpatient and ambulatory care facilities. Major trends in the forecast period include rising prevalence of shingles in aging population, increasing adoption of non-opioid pain management therapies, growing use of transdermal and topical pain relief solutions, higher demand for long-term chronic pain management, improved awareness and early diagnosis of phn.

Global Postherpetic Neuralgia (PHN) Market Segmentation

1) By Type: Patches, Drugs, Opioids 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End Users: Hospitals, Clinics, Other End Users Subsegments: 1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches 2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs 3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Is The Driver Of The Postherpetic Neuralgia (PHN) Market?

The increasing prevalence of chronic pain conditions is expected to propel the growth of the postherpetic neuralgia (PHN) market going forward. Chronic pain refers to persistent or recurring pain lasting more than 3 months, often continuing beyond the usual course of an illness or injury and affecting a person's daily functioning and quality of life. The prevalence of chronic pain conditions is due to the aging population, as older adults are more prone to degenerative diseases like arthritis and neuropathy that lead to persistent pain. Postherpetic neuralgia is helpful for chronic pain research as it provides a clear model to study nerve-related pain mechanisms and evaluate long-term treatment strategies. For instance, in January 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department, around 18.4% of people aged 16 and over reported having a long-term musculoskeletal (MSK) condition in 2023, marking a rise from 17.6% in 2022. Therefore, the increasing prevalence of chronic pain conditions is driving the growth of the postherpetic neuralgia (PHN) industry.

Key Players In The Global Postherpetic Neuralgia (PHN) Market

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Global Postherpetic Neuralgia (PHN) Market Trends and Insights

Major companies operating in the postherpetic neuralgia (PHN) market are focusing on obtaining regulatory approvals to expand their product portfolios, gain competitive advantage, and meet the significant unmet clinical need for more effective and tolerable treatments. Regulatory approvals refer to the official permissions granted by government health authorities allowing a drug or treatment to be legally marketed and used for a specific medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, received final the United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). The gabapentin tablets are intended for treating PHN, a type of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing starts at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

What Are Latest Mergers And Acquisitions In The Postherpetic Neuralgia (PHN) Market?

In September 2023, Adalvo Limited, a Malta-based pharmaceutical company focusing primarily on selling services to companies, partnered with Lotus Pharmaceutical Co. Ltd. to launch Gabapentin ER tablets in South Korea. This collaboration aims to enhance patient access to innovative and effective treatments by introducing Gabapentin ER in South Korea, strengthening their presence in the neurology market, and expanding their portfolios with high-value pharmaceutical products. Lotus Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical company that manufactures medication for postherpetic neuralgia (PHN).

Regional Insights

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Postherpetic Neuralgia (PHN) Market?

The postherpetic neuralgia (PHN) market includes revenues earned by entities by providing services such as medical consultation, pain management services, topical treatment application, physical therapy and nerve block or injections. The market value includes the value of related goods sold by the service provider or included within the service offering. The postherpetic neuralgia (PHN) market consists of sales of anticonvulsants, amitriptyline, tramadol, oxycodone, and nortriptyline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Postherpetic Neuralgia (PHN) Market Report 2026?

The postherpetic neuralgia (phn) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the postherpetic neuralgia (phn) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.